|
|
Vaccine Detail
|
Recombinant Adenovirus-p53 SCH-58500 Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Adenovirus-p53 SCH-58500 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007069
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- NF2
gene engineering:
- WT1
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- human TP53 (P53)
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: The vaccine is prepared using a replication-defective recombinant Ad type 5 (Atencio et al., 2006).
- Description: This is for Colon Cancer (NCT00002960). A genetically-engineered adenovirus that contains the gene that encodes the human tumor-suppressor protein p53 with potential antineoplastic activity. Recombinant adenovirus-p53 SCH-58500 delivers p53 into tumor cells, which may result in p53-mediated cell cycle arrest and apoptosis (NCIT_C2423).
|
| Host Response |
|
|
| References |
Atencio et al., 2006: Atencio IA, Grace M, Bordens R, Fritz M, Horowitz JA, Hutchins B, Indelicato S, Jacobs S, Kolz K, Maneval D, Musco ML, Shinoda J, Venook A, Wen S, Warren R. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial. Cancer gene therapy. 2006; 13(2); 169-181. [PubMed: 16082381].
NCIT_C2423: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2423]
NCT00002960: [https://clinicaltrials.gov/ct2/show/NCT00002960?term=Recombinant+Adenovirus+p53+SCH+58500&rank=1]
|
|
